Orthofix Medical (NASDAQ:OFIX) Raised to "Strong-Buy" at Barrington Research

Barrington Research upgraded shares of Orthofix Medical (NASDAQ:OFIX - Free Report) to a strong-buy rating in a research note issued to investors on Monday morning, Marketbeat.com reports. Barrington Research currently has $16.00 price objective on the medical device company's stock. Barrington Research also issued estimates for Orthofix Medical's Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($3.04) EPS, Q1 2026 earnings at ($0.83) EPS, Q2 2026 earnings at ($0.67) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($2.34) EPS and FY2027 earnings at ($1.64) EPS.

OFIX has been the topic of a number of other research reports. JMP Securities reissued a "market perform" rating on shares of Orthofix Medical in a report on Friday, June 6th. Canaccord Genuity Group reissued a "buy" rating and issued a $24.00 target price on shares of Orthofix Medical in a research note on Wednesday, February 26th. Wall Street Zen raised Orthofix Medical from a "sell" rating to a "hold" rating in a research note on Saturday, June 14th. Finally, Roth Mkm reiterated a "buy" rating and set a $22.00 price objective on shares of Orthofix Medical in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $21.50.

Orthofix Medical Stock Performance

Shares of NASDAQ:OFIX traded up $0.17 during midday trading on Monday, reaching $11.04. 421,082 shares of the company traded hands, compared to its average volume of 283,759. Orthofix Medical has a 12 month low of $10.24 and a 12 month high of $20.73. The firm has a market capitalization of $432.55 million, a price-to-earnings ratio of -2.99 and a beta of 0.80. The company has a quick ratio of 1.50, a current ratio of 2.71 and a debt-to-equity ratio of 0.38. The firm's fifty day moving average price is $11.89 and its two-hundred day moving average price is $15.29.

Insiders Place Their Bets

In related news, CEO Massimo Calafiore bought 10,000 shares of the company's stock in a transaction that occurred on Friday, May 9th. The stock was bought at an average cost of $12.54 per share, for a total transaction of $125,400.00. Following the acquisition, the chief executive officer now directly owns 234,603 shares of the company's stock, valued at $2,941,921.62. The trade was a 4.45% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jorge Andres Cedron sold 3,816 shares of the business's stock in a transaction that occurred on Wednesday, April 16th. The shares were sold at an average price of $13.31, for a total value of $50,790.96. Following the completion of the sale, the insider now owns 42,500 shares of the company's stock, valued at $565,675. The trade was a 8.24% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders acquired 112,250 shares of company stock valued at $1,380,970 and sold 7,620 shares valued at $91,168. 1.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Orthofix Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Lazard Asset Management LLC purchased a new stake in Orthofix Medical in the fourth quarter worth about $45,000. US Bancorp DE raised its position in shares of Orthofix Medical by 684.6% in the 1st quarter. US Bancorp DE now owns 5,673 shares of the medical device company's stock worth $93,000 after acquiring an additional 4,950 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Orthofix Medical in the 4th quarter valued at approximately $112,000. Tower Research Capital LLC TRC boosted its position in shares of Orthofix Medical by 120.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company's stock valued at $148,000 after purchasing an additional 4,627 shares in the last quarter. Finally, Strs Ohio purchased a new stake in Orthofix Medical in the first quarter worth $150,000. Institutional investors own 89.76% of the company's stock.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.